<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Radiat Oncol</journal-id>
      <journal-title-group>
        <journal-title>Radiation Oncology (London, England)</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1748-717X</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21272369</article-id>
      <article-id pub-id-type="pmc">3040152</article-id>
      <article-id pub-id-type="publisher-id">1748-717X-6-10</article-id>
      <article-id pub-id-type="doi">10.1186/1748-717X-6-10</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Quantitative assessment of inter-observer variability in target volume delineation on stereotactic radiotherapy treatment for pituitary adenoma and meningioma near optic tract</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Yamazaki</surname>
            <given-names>Hideya</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>hideya10@hotmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Shiomi</surname>
            <given-names>Hiroya</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <xref ref-type="aff" rid="I8">8</xref>
          <email>shiomi@radonc.med.osaka-u.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Tsubokura</surname>
            <given-names>Takuji</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>ttsubo@koto.kpu-m.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Kodani</surname>
            <given-names>Naohiro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>kodani@koto.kpu-m.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Nishimura</surname>
            <given-names>Takuya</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>t-nishi@koto.kpu-m.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Aibe</surname>
            <given-names>Norihiro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>a-ib-n24@koto.kpu-m.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Udono</surname>
            <given-names>Hiroki</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>hirudono@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A8">
          <name>
            <surname>Nishikata</surname>
            <given-names>Manabu</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>hirudono@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A9">
          <name>
            <surname>Baba</surname>
            <given-names>Yoshimi</given-names>
          </name>
          <xref ref-type="aff" rid="I5">5</xref>
          <email>ybaba@kyokuto.or.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A10">
          <name>
            <surname>Ogita</surname>
            <given-names>Mikio</given-names>
          </name>
          <xref ref-type="aff" rid="I6">6</xref>
          <email>ogi@orange.ocn.ne.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A11">
          <name>
            <surname>Yamashita</surname>
            <given-names>Koichi</given-names>
          </name>
          <xref ref-type="aff" rid="I7">7</xref>
          <email>k-yamashita@oka-nsc.com</email>
        </contrib>
        <contrib contrib-type="author" id="A12">
          <name>
            <surname>Kotsuma</surname>
            <given-names>Tadayuki</given-names>
          </name>
          <xref ref-type="aff" rid="I8">8</xref>
          <email>tkotsuma@radonc.med.osaka-u.ac.jp</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602 - 8566 Japan</aff>
      <aff id="I2"><label>2</label>CyberKnife Center, Soseikai General Hospital,126 Kami-Misu, Shimotoba Fushimi-ku, Kyoto Japan</aff>
      <aff id="I3"><label>3</label>CyberKnife Center, Tobata Kyoritsu Hospital, Sawami 2 - 5 - 1, Tobata-ku, Kita-Kyusyu, Fukuoka Japan</aff>
      <aff id="I4"><label>4</label>Toyama Cyberknife Center, Hiyodorijima 1837 - 5, Toyama, Toyama Japan</aff>
      <aff id="I5"><label>5</label>CyberKnife Center, Okayama Kyokuto Hospital, Kurata 567 - 1, Naka-ku, Okayama, Okayama Japan</aff>
      <aff id="I6"><label>6</label>Radiotherapy Department, Fujimoto Hayasuzu Hospital, Hayasuzu 17 - 1, Miyakonojo, Miyazaki 885 - 0055, Japan</aff>
      <aff id="I7"><label>7</label>Tokyo CyberKnife Center, 27 - 1 Negishi, Machida, Tokyo 194 - 0034, Japan</aff>
      <aff id="I8"><label>8</label>Department of Radiation Oncology, Osaka University Medical School, 2 - 2 Yamadaoka Suita, Osaka Japan</aff>
      <pub-date pub-type="collection">
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>27</day>
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <volume>6</volume>
      <fpage>10</fpage>
      <lpage>10</lpage>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>12</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>1</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2011 Yamazaki et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Yamazaki et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.ro-journal.com/content/6/1/10"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>To assess inter-observer variability in delineating target volume and organs at risk in benign tumor adjacent to optic tract as a quality assurance exercise.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>We quantitatively analyzed 21 plans made by 11 clinicians in seven CyberKnife centers. The clinicians were provided with a raw data set (pituitary adenoma and meningioma) including clinical information, and were asked to delineate the lesions and create a treatment plan. Their contouring and plans (10 adenoma and 11 meningioma plans), were then compared. In addition, we estimated the influence of differences in contouring by superimposing the respective contours onto a default plan.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>The median planning target volume (PTV) and the ratio of the largest to the smallest contoured volume were 9.22 cm<sup>3 </sup>(range, 7.17 - 14.3 cm<sup>3</sup>) and 1.99 for pituitary adenoma, and 6.86 cm<sup>3 </sup>(range 6.05 - 14.6 cm<sup>3</sup>) and 2.41 for meningioma. PTV volume was 10.1 &#xB1; 1.74 cm<sup>3 </sup>for group 1 with a margin of 1 -2 mm around the CTV (n = 3) and 9.28 &#xB1; 1.8 cm<sup>3</sup>(p = 0.51) for group 2 with no margin (n = 7) in pituitary adenoma. In meningioma, group 1 showed larger PTV volume (10.1 &#xB1; 3.26 cm<sup>3</sup>) than group 2 (6.91 &#xB1; 0.7 cm<sup>3</sup>, p = 0.03). All submitted plan keep the irradiated dose to optic tract within the range of 50 Gy (equivalent total doses in 2 Gy fractionation). However, contours superimposed onto the dose distribution of the default plan indicated that an excessive dose 23.64 Gy (up to 268% of the default plan) in pituitary adenoma and 24.84 Gy (131% of the default plan) in meningioma to the optic nerve in the contours from different contouring.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Quality assurance revealed inter-observer variability in contour delineation and their influences on planning for pituitary adenoma and meningioma near optic tract.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Target delineation is an important issue in radiation oncology, especially for image-guided, high-precision radiotherapy [<xref ref-type="bibr" rid="B1">1</xref>]. With increasing conformity of dose delivery, inter-observer variability in tumor identification and delineation plays an ever more critical role, even for uncomplicated lesions [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. Although inter-observer variability in contouring is a well-known fact, we could not find any data on variability in the contouring of benign tumors near the optic tract.</p>
      <p>Pituitary adenoma and meningioma are regarded as benign tumors and are rarely treated by radiotherapy if surgery can be performed. However, in cases that are ineligible for surgery due to a risk of excessive surgical complications, radiotherapy can play an important role in treatment for these benign tumors. Radiotherapy was initially performed using conventional technologies (Co-60 or Linac-based units) [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Stereotactic, single-fraction radiosurgery (SRS) using the Gamma knife was then begun, followed shortly thereafter by stereotactic radiotherapy (SRT) at a number of institutes [<xref ref-type="bibr" rid="B9">9</xref>]. The SRT experience for such tumors has been insufficient to develop a consensus on optimal treatment parameters, including prescribed dose and fractionation, especially for hypofractionated SRT. This lack of consensus applies as well to contouring of the planning target volume (PTV).</p>
      <p>Therefore, we conducted a multi-institutional study in which participating radiation oncologists delineated tumors and organs at risk (OARs) and created treatment plans using inverse planning software for the CyberKnife System (Accuray, Sunnyvale CA, USA). Participants created treatment plans for two patients, one with pituitary adenoma and second with meningioma. Variability in contouring, planning target volumes, prescribed doses, and doses to OARs was assessed. In addition, we examined the influence of different contouring especially optic tract by superimposing each contour onto the default plan, and we visualized dose distribution using prescribed dose 3-D rendering.</p>
    </sec>
    <sec sec-type="methods">
      <title>Methods</title>
      <p>Enhanced CT images for Case 1 (pituitary adenoma) and CT and MRI images for Case 2 (meningioma) were obtained at Soseikai General Hospital and sent via internet to seven CyberKnife institutes. For Case 1, CT images were acquired with a SOMATOM Volume Access scanner (Siemens AG, Munchen, Germany) at a 2-mm slice thickness. For Case 2, Contrast enhanced CT images were obtained with a Brilliance CT 64 scanner (Royal Philips Electronics, Euronext: PHIA, Eindhoven, Holland) at a 1.25-mm slice thickness (Default; CT level 35, window 75). MRI images were obtained by an Achieve 1.5 scanner (Royal Philips Electronics, Euronext: PHIA, Eindhoven, Holland) using a 4-mm slice gapless scan (TE 10 ms, TR 450 ms, FA 70&#xB0;, SPIR). At each CyberKnife institute, the images were transferred to a treatment planning system (TPS; MultiPlan or OnTarget, Accuray) to create a radiotherapy plan for CyberKnife stereotactic radiotherapy (SRT). Participating physicians were required to submit both the printed materials used in their routine clinical work and raw data.</p>
      <p>From seven CyberKnife centers, 11 radiation oncologists submitted plans and raw data for the meningioma and 10 for the pituitary adenoma. The collected data contained target volume contours, organs at risk (OARs), and minimum and maximum irradiated dose for those structures. Maximum and minimum doses for the PTV and the maximum dose for OARs were analyzed. Uniformity of dose distribution was assessed in terms of the minimum and maximum prescribed dose for the PTV.</p>
      <p>The raw treatment plan data in TPS format were also submitted and analyzed using ShioRIS and ShioRIS-2 (software developed in-house by author H. S.). We superimposed those contours on our default plan (created by author T. T. in Soseikai General Hospital and confirmed by other two physicians), and examined differences in the dose-volume histogram (DVH) for each contour to estimate a prescribed dose for each contoured PTV and organs at risk. The equation; equivalent total doses, EQD2 = n &#xD7; d &#xD7; (&#x3B1;/&#x3B2; + d)/(&#x3B1;/&#x3B2; + 2); the dose that would be equivalent to a 2 Gy fractionation was used for the calculation, with EQD2<sub>10</sub>; &#x3B1;/&#x3B2; = 10 for PTV and EQD2<sub>2</sub>; &#x3B1;/&#x3B2; = 2 for OARs. Next, comparison of dose distribution and dose volume renderings for the prescribed dose were analyzed for the pituitary adenoma using ShioRIS-2 in 9 contours.</p>
      <p>Generally, treatment plan was made according to the guideline of radiotherapy planning published by Japanese society for therapeutic radiology and oncology 2008 (Table <xref ref-type="table" rid="T1">1</xref>)[<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Postsurgical areas are not included intentionally in this trial. However, no consensus was obtained in hypofractionated SRT.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Reference for planning of pituitary adenoma and meningioma</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th/>
              <th align="left">Pituitary adenoma</th>
              <th align="left">Meningioma</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" colspan="3">
                <italic>PTV definitions</italic>
              </td>
            </tr>
            <tr>
              <td/>
              <td align="left">PTV = CTV + 1 mm (CTV = GTV),</td>
              <td align="left">PTV = CTV + 1 mm (CTV = GTV)</td>
            </tr>
            <tr>
              <td/>
              <td align="left">PTV = CTV + 2 - 4 mm (CTV = GTV)</td>
              <td align="left">PTV = CTV + 2 - 3 mm (CTV = GTV)</td>
            </tr>
            <tr>
              <td align="left" colspan="3">
                <italic>Prescribed dose</italic>
              </td>
            </tr>
            <tr>
              <td align="left">SRS</td>
              <td align="left">15 - 20 Gy marginal dose, 25 Gy or more for secreting pituitary adenoma</td>
              <td align="left">11 - 18 Gy marginal dose (recommended for 14 Gy or more)</td>
            </tr>
            <tr>
              <td align="left">Conventional fractionated SRT</td>
              <td/>
              <td align="left">isocenter 45 - 68 Gy/daily 1.8 Gy/fr., D95 50 - 56 Gy/daily 2 Gy/fr.</td>
            </tr>
            <tr>
              <td align="left">SRT</td>
              <td align="left">45 - 50 Gy/25 - 28 fr.</td>
              <td align="left">2 Gy/fr.</td>
            </tr>
            <tr>
              <td/>
              <td/>
              <td/>
            </tr>
            <tr>
              <td align="left">
                <italic>Constrains for organs at risk</italic>
                <italic>
                  <sup>[11]</sup>
                </italic>
              </td>
              <td/>
              <td/>
            </tr>
            <tr>
              <td align="left">SRS</td>
              <td align="left">Optic tract &lt; 8 - 10 Gy,</td>
              <td/>
            </tr>
            <tr>
              <td/>
              <td/>
              <td/>
            </tr>
            <tr>
              <td align="left">Conventional fractionated</td>
              <td/>
              <td/>
            </tr>
            <tr>
              <td align="left">SRT</td>
              <td align="left">Optic tract 50 Gy/25 fr</td>
              <td/>
            </tr>
            <tr>
              <td/>
              <td/>
              <td/>
            </tr>
            <tr>
              <td/>
              <td align="left">Spinal cord &lt; 50 Gy (10 cm or less in length)</td>
              <td/>
            </tr>
            <tr>
              <td/>
              <td align="left">Retina &lt; 45 Gy</td>
              <td/>
            </tr>
            <tr>
              <td/>
              <td align="left">Lens &lt; 10 Gy</td>
              <td/>
            </tr>
            <tr>
              <td/>
              <td align="left">Brain stem &lt; 60 Gy (1/3 volume)</td>
              <td/>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>SRS; stereotactic radiosurgery, SRT; stereotactic radiotherapy,</p>
          <p>GTV; gross tumor volume, CTV; clinical treatment volume, PTV; planning target volume, fr.; fraction,</p>
          <p>D95; irradiation dose that included 95% volume of PTV</p>
        </table-wrap-foot>
      </table-wrap>
      <sec>
        <title>Case 1. Pituitary adenoma</title>
        <p>This patient is a 46-year-old male with pituitary adenoma. He initially presented 4 years before with visual disturbance, and was diagnosed as having a pituitary adenoma. He underwent two surgical interventions, resulting in loss of vision in the right eye; vision was maintained in the left eye. The adenoma gradually progressed, eventually requiring SRT using 25 Gy in 5 equal fractions (5 Gy &#xD7; 5 times in consecutive 5 days) for a minimum coverage of 90% of the PTV (D90). Default plan used CTV = GTV and PTV = CTV + 1 mm. Conformity index was 1.14. Prescribed doses for OARs are depicted in Table <xref ref-type="table" rid="T2">2</xref>.</p>
        <table-wrap id="T2" position="float">
          <label>Table 2</label>
          <caption>
            <p>Plan characteristics</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th/>
                <th align="left" colspan="2">Meningioma</th>
                <th align="left">EQD2<sub>2</sub> (Gy)</th>
                <th align="left" colspan="2">Pituitary adenoma</th>
                <th align="left">EQD2<sub>10</sub> (Gy)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left">No of plan</td>
                <td align="left">11</td>
                <td/>
                <td/>
                <td align="left">10</td>
                <td/>
                <td/>
              </tr>
              <tr>
                <td align="left">Tumor</td>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
              </tr>
              <tr>
                <td align="center">Volume of PTV<break/>(cm<sup>3</sup>)</td>
                <td/>
                <td align="left">8.06 &#xB1; 2.45<break/></td>
                <td/>
                <td/>
                <td align="left">9.53 &#xB1; 1.75<break/></td>
                <td/>
              </tr>
              <tr>
                <td align="center">Prescribed dose</td>
                <td align="left">5</td>
                <td align="left">30 Gy/5 fr.</td>
                <td align="left">40</td>
                <td align="left">4</td>
                <td align="left">25 Gy/5 fr.</td>
                <td align="left">31.3</td>
              </tr>
              <tr>
                <td/>
                <td align="left">1</td>
                <td align="left">16 Gy/1 fr.</td>
                <td align="left">34.6</td>
                <td align="left">2</td>
                <td align="left">21 Gy/3 fr.</td>
                <td align="left">29.8</td>
              </tr>
              <tr>
                <td/>
                <td align="left">1</td>
                <td align="left">21 Gy/3 fr.</td>
                <td align="left">29.8</td>
                <td align="left">1</td>
                <td align="left">22.5 Gy/3 fr.</td>
                <td align="left">32.8</td>
              </tr>
              <tr>
                <td/>
                <td align="left">1</td>
                <td align="left">24 Gy/5 fr.</td>
                <td align="left">29.6</td>
                <td align="left">2</td>
                <td align="left">24 Gy/5 fr.</td>
                <td align="left">29.6</td>
              </tr>
              <tr>
                <td/>
                <td align="left">1</td>
                <td align="left">23 Gy/3 fr.</td>
                <td align="left">33.9</td>
                <td align="left">1</td>
                <td align="left">24 Gy/3 fr.</td>
                <td align="left">36</td>
              </tr>
              <tr>
                <td/>
                <td align="left">1</td>
                <td align="left">24 Gy/3 fr.</td>
                <td align="left">36</td>
                <td/>
                <td/>
                <td/>
              </tr>
              <tr>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td align="left">s</td>
              </tr>
              <tr>
                <td align="center">Minimal dose/prescribed dose<break/>(%)</td>
                <td/>
                <td align="left">83.7 &#xB1; 9 range 72 - 90<break/></td>
                <td/>
                <td/>
                <td align="left">80 &#xB1; 12 range 60 - 99<break/></td>
                <td/>
              </tr>
              <tr>
                <td align="center">Maximal dose/prescribed dose<break/>(%)</td>
                <td/>
                <td align="left">122 &#xB1; 15 range 110 - 157<break/></td>
                <td/>
                <td/>
                <td align="left">129 &#xB1; 17 range 105 - 157<break/></td>
                <td/>
              </tr>
              <tr>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
              </tr>
              <tr>
                <td align="left">OARs</td>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
              </tr>
              <tr>
                <td align="left">(Gy)</td>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
                <td/>
              </tr>
              <tr>
                <td align="center">Left eye</td>
                <td/>
                <td align="left">0.12 - 2.25</td>
                <td/>
                <td/>
                <td align="left">0.02 - 4.48</td>
                <td/>
              </tr>
              <tr>
                <td align="center">Right eye</td>
                <td/>
                <td align="left">3.07 - 18.6</td>
                <td/>
                <td/>
                <td align="left">0.05 - 4.52</td>
                <td/>
              </tr>
              <tr>
                <td align="center">Brain stem</td>
                <td/>
                <td align="left">4.97 - 15.4</td>
                <td align="left">4.5 - 19.5</td>
                <td/>
                <td align="left">17.3 - 24.74</td>
                <td align="left">30.0 - 42.9</td>
              </tr>
              <tr>
                <td align="center">Optic chiasm</td>
                <td/>
                <td align="left">4.61 - 15.4</td>
                <td align="left">4.1 -- 19.9</td>
                <td/>
                <td align="left">16.6 - 26.4</td>
                <td align="left">22 -- 48</td>
              </tr>
              <tr>
                <td align="center">Left lens</td>
                <td/>
                <td align="left">0.01 - 2.00</td>
                <td/>
                <td/>
                <td align="left">0.03 - 4.08</td>
                <td/>
              </tr>
              <tr>
                <td align="center">Right lens</td>
                <td/>
                <td align="left">0.88 - 6.68</td>
                <td/>
                <td/>
                <td align="left">0.13 - 3.81</td>
                <td/>
              </tr>
              <tr>
                <td align="center">Left optic nerve</td>
                <td/>
                <td align="left">0.79 - 8.96</td>
                <td align="left">0.4 - 8.5</td>
                <td/>
                <td align="left">12.4 - 23.4</td>
                <td align="left">23 - 50</td>
              </tr>
              <tr>
                <td align="center">Right optic nerve</td>
                <td/>
                <td align="left">7.93 -- 26.4</td>
                <td align="left">14.6 - 47.9</td>
                <td/>
                <td align="left">0.37 - 23.4</td>
                <td align="left">17.5 -- 57.5</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>EQD2 = n &#xD7; d &#xD7; (&#x3B1;/&#x3B2;+d)/(&#x3B1;/&#x3B2;+2), EQD2<sub>10</sub>; &#x3B1;/&#x3B2; = 10 for PTV and EQD2<sub>2</sub>; &#x3B1;/&#x3B2; = 2 for organs at risk</p>
            <p>OARs; organs at risk, fr.; fraction</p>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec>
        <title>Case 2. Meningioma</title>
        <p>This patient is a 50-year-old female with sphenoid ridge meningioma. She experienced back pain while performing nursing care for her mother three years before, and was diagnosed at the time as having a meningioma. During several years of follow-up the tumor grew, eventually requiring surgical intervention. Thereafter, a residual tumor grew slowly and she was recommended for further treatment with the CyberKnife. She received SRT using 30 Gy in 5 fractions (6 Gy &#xD7; 5 times in consecutive 5 days) for D90. Default plan used CTV = GTV and PTV = CTV + 1 mm. Conformity index was 1.12. Those plans were verified by other two physicians, and used as a control references.</p>
      </sec>
      <sec>
        <title>Statistical Analysis</title>
        <p>All statistical analyses were carried out with the Statview-v5.0 software program. Student's t-test was used for normally distributed data and the Mann Whitney U-test for skewed data. Percentages were analyzed with the Chi-square test. A value of <italic>p </italic>&lt; 0.05 was considered to be statistically significant.</p>
      </sec>
    </sec>
    <sec>
      <title>Results</title>
      <sec>
        <title>Case 1. pituitary adenoma</title>
        <p>Each contour was superimposed on the original CT images (Figure <xref ref-type="fig" rid="F1">1</xref>). Three physicians used PTV = CTV + 1 mm (group 1 with a margin of 1 mm around the CTV). Seven used a protocol in which the PTV = CTV = GTV (group 2 with no margin). The median PTV was 9.22 cm<sup>3 </sup>(range, 7.17 - 14.3 cm<sup>3</sup>; Figure <xref ref-type="fig" rid="F2">2</xref>); the ratio of the largest to the smallest contoured volume was 1.99. Group 1 used PTV volume 10.1 &#xB1; 1.74 cm<sup>3 </sup>and group 2 used 9.28 &#xB1; 1.8 cm<sup>3 </sup>(p = 0.51, n.s.). Four physicians used D90 (9.37 &#xB1; 0.4 cm<sup>3</sup>) and six used D95 (9.7 &#xB1; 2.6 cm<sup>3</sup>, n.s. vs. D90 group) as dose prescription methods. The average of the smallest prescribed dose divided by the prescribed dose in the PTV was 80% and the mean maximum dose was 129%. The irradiated doses for the OARs are depicted in Table <xref ref-type="table" rid="T2">2</xref>. The irradiated dose to the intact left optic nerve was kept below 50 Gy (EQD2<sub>2</sub>) according to guideline [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>], whereas the right optic nerve in which vision was already lost received 57.5 Gy (EQD2<sub>2</sub>). Thus, no plan exceeded the critical dose for the OARs [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Next, we analyzed DVHs by superimposing the dispatched contours onto the original default plan (25 Gy in 5 fractions for D90; Figure <xref ref-type="fig" rid="F3">3</xref>). The prescribed dose for D90 varied from 23.34 - 24.78 Gy (median: 24.68 Gy). Maximum dose for left optic nerve ranged from 8.78 - 23.64 Gy (median: 12.41 Gy). Although the default plan delivered a maximum dose of 8.79 Gy to the left optic nerve, the maximum dose was increased up to 23.64 Gy (268% higher dose than the default plan) in the comparison contours. Therefore, contour deviation could cause an unintended higher dose delivered to the OARs.</p>
        <fig id="F1" position="float">
          <label>Figure 1</label>
          <caption>
            <p><bold>Contours superimposed on the default CT image (Pituitary adenoma)</bold>. (a) (b) axial section (c) sagittal section (d) coronal section.</p>
          </caption>
          <graphic xlink:href="1748-717X-6-10-1"/>
        </fig>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <p><bold>Contours superimposed on the default CT image (Meningioma)</bold>. (a) (b) (c) axial section (d) sagittal section (e) coronal section The red lines depict planning target volumes, and the green lines depict delineations of organs at risk from each clinician.</p>
          </caption>
          <graphic xlink:href="1748-717X-6-10-2"/>
        </fig>
        <fig id="F3" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Variation in planning treatment volume (PTV) in pituitary adenoma and meningioma cases.</p>
          </caption>
          <graphic xlink:href="1748-717X-6-10-3"/>
        </fig>
      </sec>
      <sec>
        <title>Case 2. meningioma</title>
        <p>Each contour was superimposed on the original CT images (Figure <xref ref-type="fig" rid="F2">2</xref>). Two physicians used PTV = CTV + 1 mm, and one used PTV = CTV + 1 - 2 mm (group 1 with a margin of 1 mm around the CTV). Seven used protocol PTV = CTV = GTV (group 2 with no margin). The median PTV was 6.86 cm<sup>3 </sup>(range, 6.04 - 14.6 cm<sup>3</sup>) (Figure <xref ref-type="fig" rid="F3">3</xref>), and the ratio of the largest to the smallest contoured volume was 2.41. Group 1 used larger PTV volume (10.1 &#xB1; 3.26 cm<sup>3</sup>) than group 2 (6.91 &#xB1; 0.7 cm<sup>3</sup>, p = 0.03). Four physicians used D90 (6.7 &#xB1; 0.4 cm<sup>3</sup>), and seven used D95 (8.1 &#xB1; 1.2 cm<sup>3</sup>, vs. D90 group) as a prescribed dose. The average minimum prescribed dose (%) in the PTV was 83.7% and the mean maximum dose was 122%. The prescribed dose for OARs was assessed in 11 cases and is depicted in Table <xref ref-type="table" rid="T2">2</xref>. No plan exceeded the determined critical dose for OARs [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Next, the DVHs were reanalyzed by superimposing the contours from participants onto the default plan (Figure <xref ref-type="fig" rid="F4">4</xref>). The median value for the D90 prescribed dose for PTV was 30.29 Gy (24.24 - 30.66 Gy), and the maximum dose received by the right optic nerve had a median value of 19.39 Gy (16.21 - 24.84 Gy). Therefore, some plans used 24.24 Gy as a D90 prescribed dose (19% lower dose than anticipated) when using their contoured PTV. In addition, a higher maximum dose of 24.84 Gy (131% of the default plan dose of 18.9 Gy) was delivered for the right optic nerve in the contours used in some institutes.</p>
        <fig id="F4" position="float">
          <label>Figure 4</label>
          <caption>
            <p><bold>Influence of different contours on the DVH analysis</bold>. Each contour was layered over the original default plan (Soseikai General Hospital). The dose calculation was made by ShioRIS, and the DVH was calculated using ShioRIS-2. a) Pituitary adenoma:10 contours Left panel. PTV. Default D90 = 25 Gy/5 fractions. According to the applied contours, the D90 median dose was 24.68 Gy (23.34 - 24.78 Gy). Right panel. OAR (left optic nerve). Left optic nerve received 8.79 Gy in default plan (made by T. T.), median 12.41 Gy (8.78 - 23.64 Gy; 23.64 Gy = 268% of default plan) b) Meningioma: 11 contours Left panel. PTV. Default D90 = 30 Gy/5 fractions. According to the applied contours, the D90 median dose was 30.29 Gy (24.24 - 30.66 Gy). Right panel. OAR (right optic nerve). The right optic nerve received a median dose of 19.39 Gy (16.21 - 24.84 Gy; 18.9 Gy in the default plan). Therefore, some plans used 24.24 Gy as a D90 prescribed dose (19% lower dose than anticipated in widen PTV group) when using their contoured PTV. In addition, a higher maximum dose of 24.84 Gy (131% higher dose than default plan 18.9 Gy) was delivered to the right optic nerve in contours used in some institutes.</p>
          </caption>
          <graphic xlink:href="1748-717X-6-10-4"/>
        </fig>
      </sec>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>Inter-observer variation is a well-known problem in medical practice. Gardenia et al. first reported on this issue in the 1950 s [<xref ref-type="bibr" rid="B3">3</xref>], and it became a subject for discussion in the radiotherapeutic community in the 1970 s. In the 1990 s, many articles were published about inter-observer variation for a variety of cancers: prostate cancer [<xref ref-type="bibr" rid="B4">4</xref>], brain tumors [<xref ref-type="bibr" rid="B5">5</xref>], breast cancer [<xref ref-type="bibr" rid="B6">6</xref>] head and neck cancer [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>], and lung cancer [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. However, we were unable to find any papers that examined inter-observer variation for pituitary adenoma and meningioma; to the best of our knowledge, this is the first such report.</p>
      <p>DVHs analysis by superimposing different contours from multiple clinicians onto the default treatment plan showed higher maximal dose for optic tract (Figure <xref ref-type="fig" rid="F3">3</xref>). It was increased to 23.64 Gy (268% higher dose than default plan) for the pituitary adenoma and 19.39 Gy (131%) for the meningioma. These results imply that contour deviations across plans could easily cause unexpectedly higher doses to OARs. On the other hand, some comparison plans prescribed 19% lower does than the default 24.24 Gy in the meningioma. Although the dose to PTV is not a matter of this study because it will be changed by physician's decision (PTV definition etc.), we can suggest that there are such a variety of different SRT plans using same CT images.</p>
      <p>Several limitations should be considered in our study. At first, BED assessment is not validated in hypofractionated SRT, however it is an only method to compare different fractionation quantitatively at present. Next, although we used default plan as a control references after confirmed by other two physicians, there is neither consensus in contouring nor planning in these area, so that in fact it is only simulation examination. Thirdly, although we confirmed precision of fusion software by visual inspection at least by other two physicians, accuracy of fusion is still qualified by subjective methods.</p>
      <p>To obtain reproducible outcomes using an inverse plan, consensus among the participants should be reached in advance to avoid uncertainty; for example, definitions of major violations should be provided and training sessions made available for participants to improve the conformity of their plans to an agreed upon benchmark. These results underline the importance of QA assessment for reproducible outcomes, not only in contouring and the setting of dose constraints, but also for planned dose distributions especially in a multi-clinician study. We should keep in mind the risk of such new techniques as cyberknife if the QA is not followed.</p>
      <p>In conclusion, quality assurance revealed inter-observer variability in contour delineation of pituitary adenoma and meningioma near optic tract.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>HY conceived of this study and drafted manuscript, HS made software and participated in the design of this study. TT, NK and TN participated in confirmation of default plan and the statistical analysis. HY, HS, TT, NK, TN, NA, HU, MN, YB, MO, KY and TK made plan and participated coordination and helped to draft the manuscript. All authors read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>The authors wish to thank Ms. Hitomi Fuse, Mr. Yoshiichi Murashima, Mr. Naokazu Higashinaka, and Mr. Yoshiaki Furutani for their dedicated contributions to this manuscript.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Riboldi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sharp</surname>
            <given-names>GC</given-names>
          </name>
          <name>
            <surname>Baroni</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>GT</given-names>
          </name>
          <article-title>Four-dimensional targeting error analysis in image-guided radiotherapy</article-title>
          <source>Phys Med Biol</source>
          <year>2009</year>
          <volume>54</volume>
          <fpage>5995</fpage>
          <lpage>6008</lpage>
          <pub-id pub-id-type="doi">10.1088/0031-9155/54/19/022</pub-id>
          <pub-id pub-id-type="pmid">19773606</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Yamazaki</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Nishiyama</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Tanaka</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Koiwai</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Shikama</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Ito</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Arahira</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Tamamoto</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Shibata</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Tamaki</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kodaira</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Oguchi</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Dummy run for a phase II multi-institute trial of chemoradiotherapy for unresectable pancreatic cancer: inter-observer variance in contour delineation</article-title>
          <source>Anticancer Res</source>
          <year>2007</year>
          <volume>27</volume>
          <fpage>2965</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="pmid">17695480</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gandevia</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Stradling</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Observer variation in the tomographic diagnosis of tuberuculous cavitation</article-title>
          <source>Tubercle</source>
          <year>1957</year>
          <volume>38</volume>
          <fpage>113</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.1016/S0041-3879(57)80005-1</pub-id>
          <pub-id pub-id-type="pmid">13422638</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Villeirs</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Van Vaerenbergh</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Vakaet</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Bral</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Claus</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>De Neve</surname>
            <given-names>WJ</given-names>
          </name>
          <name>
            <surname>Verstraete</surname>
            <given-names>KL</given-names>
          </name>
          <name>
            <surname>De Meerleer</surname>
            <given-names>GO</given-names>
          </name>
          <article-title>Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer</article-title>
          <source>Strahlenther Onkol</source>
          <year>2005</year>
          <volume>181</volume>
          <fpage>424</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1007/s00066-005-1383-x</pub-id>
          <pub-id pub-id-type="pmid">15995835</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Weltens</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Menten</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Feron</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Weltens</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Menten</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Feron</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bellon</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Demaerel</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Maes</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Van den Bogaert</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>van der Schueren</surname>
            <given-names>E</given-names>
          </name>
          <etal/>
          <article-title>Interobserver variations in gross tumor volume delineation of brain tumors on computed tomography and impact of magnetic resonance imaging</article-title>
          <source>Radiother Oncol</source>
          <year>2001</year>
          <volume>60</volume>
          <fpage>49</fpage>
          <lpage>59</lpage>
          <pub-id pub-id-type="doi">10.1016/S0167-8140(01)00371-1</pub-id>
          <pub-id pub-id-type="pmid">11410304</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Poortmans</surname>
            <given-names>PM</given-names>
          </name>
          <name>
            <surname>Venselaar</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Struikmans</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Hurkmans</surname>
            <given-names>CW</given-names>
          </name>
          <name>
            <surname>Davis</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Huyskens</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>van Tienhoven</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Vlaun</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Lagendijk</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Mijnheer</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>De Winter</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Van der Hulst</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Van den Bogaert</surname>
            <given-names>WF</given-names>
          </name>
          <article-title>The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922/10925 in Stage I--III breast cancer</article-title>
          <source>Int J Radiat Oncol Biol Phys</source>
          <year>2001</year>
          <volume>49</volume>
          <fpage>1399</fpage>
          <lpage>408</lpage>
          <pub-id pub-id-type="doi">10.1016/S0360-3016(00)01549-2</pub-id>
          <pub-id pub-id-type="pmid">11286848</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Stafford</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Pollock</surname>
            <given-names>BE</given-names>
          </name>
          <name>
            <surname>Foote</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Link</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Gorman</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Schomberg</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Leavitt</surname>
            <given-names>JA</given-names>
          </name>
          <article-title>Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients</article-title>
          <source>Neurosurgery</source>
          <year>2001</year>
          <volume>49</volume>
          <fpage>1029</fpage>
          <lpage>1037</lpage>
          <pub-id pub-id-type="doi">10.1097/00006123-200111000-00001</pub-id>
          <pub-id pub-id-type="pmid">11846894</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Erridge</surname>
            <given-names>SC</given-names>
          </name>
          <name>
            <surname>Conkey</surname>
            <given-names>DS</given-names>
          </name>
          <name>
            <surname>Stockton</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Strachan</surname>
            <given-names>MW</given-names>
          </name>
          <name>
            <surname>Statham</surname>
            <given-names>PF</given-names>
          </name>
          <name>
            <surname>Whittle</surname>
            <given-names>IR</given-names>
          </name>
          <name>
            <surname>Grant</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kerr</surname>
            <given-names>GR</given-names>
          </name>
          <name>
            <surname>Gregor</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Radiotherapy for pituitary adenomas: long-term efficacy and toxicity</article-title>
          <source>Radiother Oncol</source>
          <year>2009</year>
          <volume>93</volume>
          <fpage>597</fpage>
          <lpage>601</lpage>
          <pub-id pub-id-type="doi">10.1016/j.radonc.2009.09.011</pub-id>
          <pub-id pub-id-type="pmid">19900729</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Milker-Zabel</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Debus</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Thilmann</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Schlegel</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Wannenmacher</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Fractionated stereotactically guided radiotherapy and radiosurgery in the treatment of functional and nonfunctional adenomas of the pituitary gland</article-title>
          <source>Int J Radiat Oncol Biol Phys</source>
          <year>2001</year>
          <volume>50</volume>
          <fpage>1279</fpage>
          <lpage>1286</lpage>
          <pub-id pub-id-type="doi">10.1016/S0360-3016(01)01535-8</pub-id>
          <pub-id pub-id-type="pmid">11483339</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="book">
          <source>Guideline for radiotherapy planning</source>
          <publisher-name>Japanese society for therapeutic radiology and oncology Japanese College of Radiology, Japan radiological society</publisher-name>
          <ext-link ext-link-type="uri" xlink:href="http://www.kkr-smc.com/rad/guideline/2008/">http://www.kkr-smc.com/rad/guideline/2008/</ext-link>
          <comment>(in Japanese)</comment>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Emami</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Lyman</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Coia</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Goitein</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Munzenrider</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Shank</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Solin</surname>
            <given-names>LJ</given-names>
          </name>
          <name>
            <surname>Wesson</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Tolerance of normal tissue to therapeutic irradiation</article-title>
          <source>Int J Radiat Oncol Biol Phys</source>
          <year>1991</year>
          <volume>21</volume>
          <fpage>109</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="pmid">2032882</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Jeanneret-Sozzi</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Moeckli</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Valley</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Zouhair</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ozsahin</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Mirimanoff</surname>
            <given-names>RO</given-names>
          </name>
          <collab>SASRO</collab>
          <article-title>The reasons for discrepancies in target volume delineation: a SASRO study on head-and-neck and prostate cancers</article-title>
          <source>Strahlenther Onkol</source>
          <year>2006</year>
          <volume>182</volume>
          <fpage>450</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1007/s00066-006-1463-6</pub-id>
          <pub-id pub-id-type="pmid">16896591</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Geets</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Daisne</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Arcangeli</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Coche</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>De Poel</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Duprez</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Nardella</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Gr&#xE9;goire</surname>
            <given-names>V</given-names>
          </name>
          <article-title>Inter-observer variability in the delineation of pharyngo-laryngeal tumor, parotid glands and cervical spinal cord: comparison between CT-scan and MRI</article-title>
          <source>Radiother Oncol</source>
          <year>2005</year>
          <volume>77</volume>
          <fpage>25</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1016/j.radonc.2005.04.010</pub-id>
          <pub-id pub-id-type="pmid">15919126</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Steenbakkers</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Duppen</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Fitton</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Deurloo</surname>
            <given-names>KE</given-names>
          </name>
          <name>
            <surname>Zijp</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Uitterhoeve</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Rodrigus</surname>
            <given-names>PT</given-names>
          </name>
          <name>
            <surname>Kramer</surname>
            <given-names>GW</given-names>
          </name>
          <name>
            <surname>Bussink</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>De Jaeger</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Belderbos</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Hart</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Nowak</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>van Herk</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rasch</surname>
            <given-names>CR</given-names>
          </name>
          <article-title>Observer variation in target volume delineation of lung cancer related to radiation oncologist-computer interaction: a 'Big Brother' evaluation</article-title>
          <source>Radiother Oncol</source>
          <year>2005</year>
          <volume>77</volume>
          <fpage>182</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.1016/j.radonc.2005.09.017</pub-id>
          <pub-id pub-id-type="pmid">16256231</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>van Sornsen</surname>
            <given-names>JR de Koste</given-names>
          </name>
          <name>
            <surname>Senan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Underberg</surname>
            <given-names>RW</given-names>
          </name>
          <name>
            <surname>Oei</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>Elshove</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Slotman</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Lagerwaard</surname>
            <given-names>FJ</given-names>
          </name>
          <article-title>Use of CD-ROM-based tool for analyzing contouring variations in involved-field radiotherapy for stage III NSCLC</article-title>
          <source>Int J Radiat Oncol Biol Phys</source>
          <year>2005</year>
          <volume>63</volume>
          <fpage>334</fpage>
          <lpage>339</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijrobp.2005.02.016</pub-id>
          <pub-id pub-id-type="pmid">16168828</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
